Literature DB >> 16143956

Synthesis of some 2(3H)-benzoxazolone derivatives and their in-vitro effects on human leukocyte myeloperoxidase activity.

Zeynep Soyer1, Meral Bas, Aysun Pabuccuoglu, Varol Pabuccuoglu.   

Abstract

Myeloperoxidase (MPO), a heme protein expressed by polymorphonuclear leukocytes, generates potent oxidants which are proposed to contribute to tissue damage during inflammation and certain pathogenesis such as neurodegenerative disorders. In this study, twenty omega-[2-oxo-3H-benzoxazol-3-yl]-N-phenylacetamide and propionamide derivatives having substituents of different lipophilic and electronic nature on the N-phenyl ring were synthesized to evaluate the inhibitory effects on in vitro leukocyte MPO chlorinating activity. The most active compounds in the series were the derivatives bearing 2-methyl and 4-nitro substituent on the N-phenyl ring.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16143956     DOI: 10.1002/ardp.200500106

Source DB:  PubMed          Journal:  Arch Pharm (Weinheim)        ISSN: 0365-6233            Impact factor:   3.751


  4 in total

Review 1.  Myeloperoxidase: a target for new drug development?

Authors:  E Malle; P G Furtmüller; W Sattler; C Obinger
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

2.  3-Anilinomethyl-5-chloro-1,3--benzoxazol-2(3H)-one.

Authors:  Abdullah Aydın; Zeynep Soyer; Mehmet Akkurt; Orhan Büyükgüngör
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-04-28

3.  Crystal structure and theoretical study of N,N-bis-[(5-chloro-2-oxo-2,3-di-hydro-benzo[d]oxazol-3-yl)meth-yl]-2-phenyl-ethanamine.

Authors:  Abdullah Aydın; Zeynep Soyer; Mehmet Akkurt; Orhan Büyükgüngör
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2018-04-27

4.  Synthesis and hepatoprotective properties of Acanthus ilicifolius alkaloid A and its derivatives.

Authors:  Lin Liu; Hui Fan; Ping Qi; Yan Mei; Lijuan Zhou; Liping Cai; Xing Lin; Jun Lin
Journal:  Exp Ther Med       Date:  2013-06-28       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.